Anesthesiologist Michael S. Avidan, MBBCh, reproductive biologist Sarah K. England, PhD, and neurologist Timothy Miller, MD, PhD, all of Washington University School of Medicine in St. Louis, have been elected to the National Academy of Medicine, a part of the National Academy of Sciences. Membership in the organization is one of the highest honors in […]
Tag: Timothy Miller
Drug for rare form of ALS, based in part on WashU research, approved by FDA
A new drug has been approved by the Food and Drug Administration (FDA) for a rare, inherited form of amyotrophic lateral sclerosis (ALS), a paralyzing neurological disease. Known as tofersen, the drug has been shown to slow progression of the deadly disease. International clinical trials of tofersen, developed by the global biotechnology company Biogen Inc., […]
Miller receives Rainwater Prize for Brain Research
Timothy Miller, MD, PhD, the David Clayson Professor of Neurology at Washington University School of Medicine in St. Louis, has been named a winner of the Rainwater Annual Prize for Outstanding Innovation in Neurodegenerative Disease Research. The prize recognizes scientific progress that could lead to innovative, effective treatments for neurodegenerative diseases associated with the accumulation […]
Future Thoughts and Reason for Excitement in ALS: Timothy Miller, MD, PhD
“These trials don’t go without huge input and commitment from the participants and of course, their caregivers, and the clinical trial sites. I have the privilege of speaking to you about the trial as the lead author of this paper, but this is a team effort and includes a large group of people from multiple […]
Investigational drug for genetic form of ALS improves disease’s molecular signs
An investigational drug developed to treat a rare, inherited form of amyotrophic lateral sclerosis (ALS) reduced molecular signs of the fatal, paralyzing disease and curbed neurodegeneration — but at the six-month mark, the drug did not improve motor control and muscle strength, according to results from a phase 3 clinical trial led by researchers at […]
Brain trust: Symposium brings together diverse community of undergraduate neuroscientists
The WUSTL ENDURE program, which hosts the annual symposium, partners with groups across WashU and local institutions to attract top talent, provide training and mentorship opportunities, and improve the diversity of the neuroscience field. “What would happen if you lost your heart?” Ephraim Oyetunji, a rising junior studying neuroscience in the Department of Biology and […]
Experimental drug shows early promise against inherited form of ALS, trial indicates
An experimental drug for a rare, inherited form of amyotrophic lateral sclerosis (ALS) has shown promise in a phase 1/phase 2 clinical trial conducted at Washington University School of Medicine in St. Louis, Massachusetts General Hospital in Boston and other sites around the world and sponsored by the pharmaceutical company Biogen Inc. The trial indicated […]
Timothy Miller receives international innovation prize
Timothy Miller, MD, PhD, the David Clayson Professor of Neurology at Washington University School of Medicine in St. Louis, and a group of his colleagues have received the inaugural Healey Center International Prize for innovation in amyotrophic lateral sclerosis (ALS) research from the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital. […]
Antisense Drugs for Huntington’s, ALS and Prion Diseases Could Meet the Dire Need for Brain Treatments
Among the human body’s many maladies, few have stumped medical researchers like those that decimate the brain. After decades of effort, effectively treating—let alone curing—neurodegenerative disorders such as Huntington’s and Alzheimer’s disease has been a source of frustration for many, as old theories are questioned and clinical trials fail. Basic scientists have achieved some progress. […]
Experimental treatment could be ‘game-changing’ for genetic ALS, experts say
An experimental treatment for the rapidly progressive disease ALS, or amyotrophic lateral sclerosis, has been called potentially “game-changing.” The treatment, called tofersen, was found to slow the decline of muscular function associated with a genetic form of ALS in a study to be presented next week at the annual meeting of the American Academy of […]
New ALS therapy in clinical trials
Drug extends survival, reverses some neuromuscular damage in animals From the WashU School of Medicine News… About 20,000 people in the United States are living with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The invariably fatal disease kills the nerve cells that control walking, eating and breathing. Few people survive more than […]
Miller receives Essey award from neurological society
Recognized for advancing research into ALS From the WashU Newsroom… Timothy Miller, MD, PhD, the Clayson Professor of Neurology at Washington University School of Medicine in St. Louis, has received the 2018 Sheila Essey Award from the American Academy of Neurology. The award includes $50,000 to support his work on amyotrophic lateral sclerosis (ALS), commonly […]
Pursuing a precision paradigm
Why move from current standards of patient care to a more personalized approach to treatment? Experts at the School of Medicine describe today’s medical landscape as they plan for the care — and cures — of the future. From the WashU Newsroom… Of the top-grossing domestic movies of 2017 to date, three of the Top 5 […]